Literature DB >> 21658633

Antibiotic treatment of CF lung disease: from bench to bedside.

Robert Bals1, Dominique Hubert, Burkhard Tümmler.   

Abstract

Chronic infection of the respiratory tract is a hallmark of cystic fibrosis (CF). Antibiotic treatment has been used as one of the mainstays of therapy and together with other treatment modalities has resulted in increased survival of CF patients. Increasing resistance of CF-specific pathogens to various classes of antibiotics explains the need for novel antibiotic strategies. This review focuses on the future development of new antibiotic therapies, including: (1) New targets, (2) novel antibiotic regimens in CF, (3) new antibiotics, and (4) other investigational therapies. In addition, we briefly summarize developments in the area of microbial diagnostics and discuss interactions between the complex pulmonary microflora.
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21658633     DOI: 10.1016/S1569-1993(11)60019-2

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  10 in total

Review 1.  Dental caries prevalence in children and adolescents with cystic fibrosis: a qualitative systematic review and recommendations for future research.

Authors:  Donald L Chi
Journal:  Int J Paediatr Dent       Date:  2013-06-12       Impact factor: 3.455

2.  Related factors of dental caries and molar incisor hypomineralisation in a group of children with cystic fibrosis.

Authors:  S Peker; S Mete; Y Gokdemir; B Karadag; B Kargul
Journal:  Eur Arch Paediatr Dent       Date:  2014-02-26

3.  Coordinate hyperproduction of SmeZ and SmeJK efflux pumps extends drug resistance in Stenotrophomonas maltophilia.

Authors:  Virginia C Gould; Aki Okazaki; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

4.  Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.

Authors:  Cornelia B Landersdorfer; Vanessa E Rees; Rajbharan Yadav; Kate E Rogers; Tae Hwan Kim; Phillip J Bergen; Soon-Ee Cheah; John D Boyce; Anton Y Peleg; Antonio Oliver; Beom Soo Shin; Roger L Nation; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 5.  Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Authors:  M C Gaspar; W Couet; J-C Olivier; A A C C Pais; J J S Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-26       Impact factor: 3.267

6.  Cysteamine as a Future Intervention in Cystic Fibrosis Against Current and Emerging Pathogens: A Patient-based ex vivo Study Confirming its Antimicrobial and Mucoactive Potential in Sputum.

Authors:  Graham Devereux; Douglas Fraser-Pitt; Jennifer Robertson; Edward Devlin; Derry Mercer; Deborah O'Neil
Journal:  EBioMedicine       Date:  2015-08-10       Impact factor: 8.143

7.  An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic Fibrosis.

Authors:  Graham Devereux; Sandra Steele; Kairen Griffiths; Edward Devlin; Douglas Fraser-Pitt; Seonaidh Cotton; John Norrie; Henry Chrystyn; Deborah O'Neil
Journal:  Clin Drug Investig       Date:  2016-08       Impact factor: 2.859

Review 8.  Impact of rare diseases in oral health.

Authors:  A Molina-García; L Castellanos-Cosano; G Machuca-Portillo; M Posada-de la Paz
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2016-09-01

9.  Towards individualized diagnostics of biofilm-associated infections: a case study.

Authors:  Mathias Müsken; Kathi Klimmek; Annette Sauer-Heilborn; Monique Donnert; Ludwig Sedlacek; Sebastian Suerbaum; Susanne Häussler
Journal:  NPJ Biofilms Microbiomes       Date:  2017-09-28       Impact factor: 7.290

10.  Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable Pseudomonas Aeruginosa Strains via Mechanism-Based Modelling.

Authors:  Vanessa E Rees; Jürgen B Bulitta; Antonio Oliver; Roger L Nation; Cornelia B Landersdorfer
Journal:  Pharmaceutics       Date:  2019-09-12       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.